ad image

Company Info

Genentech

Genentech

Drug Discovery & Development

Overview

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
Genentech
Contributions
10 Contributions1 / 1
Genentech

Genentech Launches Oncology Clinical Trial Diversity Alliance

Genentech

PR-M06-21-031Jun 24, 2021
Genentech

Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia

Genentech

PA1285Sep 18, 2020
Genentech
FDA

FDA Accepts Application for Xolair Prefilled Syringe for Self-Administration Across All Indications

Genentech

PR-M08-20-NI-32Aug 19, 2020
Genentech
Oncology

Genentech’s Tecentriq® (ATEZOLIZUMAB) Reduced the Risk of Disease Worsening or Death in Advanced Bladder Cancer

Genentech

PR-M08-19-NI-031Aug 12, 2019
Genentech
FDA Approval

Genentech Announces FDA Approval for Venclexta Plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia

Genentech

PR-M05-19-NI-050May 17, 2019
Genentech
FDA Approval

FDA Grants Breakthrough Therapy Designation for Xolair(Omalizumab) for Food Allergies

Genentech

PR-M09-18-NI-005Sep 04, 2018
Genentech
Study Results

Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped Against Lung Cancer

Genentech

PR-M05-18-NI-116May 31, 2018
Genentech
FDA Approval

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis

Genentech

PR-M05-18-NI-064May 17, 2018
Genentech
Clinical Trials

Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib)

Genentech

PR-M05-18-NI-048May 14, 2018
Genentech
Clinical Data

New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis

Genentech

PR-M04-18-NI-88Apr 25, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0